Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

This publication has 43 references indexed in Scilit:

• Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention
  The American Journal of Cardiology, 2004
• Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes
  Circulation, 2003
• Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease
  Circulation, 2003
• Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
  Circulation, 2003
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  BMJ, 2002
• Global Burden of Cardiovascular Diseases
  Circulation, 2001
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
  The Lancet, 1996
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988